GENinCode (LON:GENI) Hits New 1-Year Low – Here’s Why

GENinCode Plc (LON:GENI) shares reached a new 52-week low during mid-day trading on Monday. The company traded as low as GBX 0.56 and last traded at GBX 0.64, with a volume of 1,374,834 shares traded. The stock had previously closed at GBX 0.64.

GENinCode Stock Performance

The company has a quick ratio of 15.88, a current ratio of 2.22 and a debt-to-equity ratio of 4.75. The firm has a 50 day moving average price of GBX 0.84 and a 200 day moving average price of GBX 0.95. The stock has a market cap of £4.81 million, a PE ratio of -0.50 and a beta of 0.59.

GENinCode (LON:GENI) last released its quarterly earnings data on Tuesday, September 29th. The company reported GBX (0.38) earnings per share for the quarter. GENinCode had a negative return on equity of 481.34% and a negative net margin of 202.42%. As a group, research analysts forecast that GENinCode Plc will post -7.13 earnings per share for the current year.

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.